Navigation Links
PROLOR Biotech To Present Preclinical Data On Its Long-Acting Clotting Factor Vlla At 2012 ASH Annual Meeting
Date:12/7/2012

t PROLOR's poster, "Factor VIIa-CTP,a Novel Long-Acting Coagulation Factor with Enhanced Long Term Haemostatic Effect and Improved Pharmacokinetics and Pharmacodynamic Properties Following IV Administration in Hemophilic Animal Models," on December 8, 2012 at 5.30 pm EST. The 2012 ASH Annual Meeting is being held December 8-11, 2012 in Atlanta, Georgia.  For more information, visit www.hematology.org/Meetings/Annual-Meeting/.

ABOUT PROLOR
PROLOR Biotech, Inc. is a clinical stage biopharmaceutical company applying unique technologies, including patented CTP technology and its long-acting reversible-pegylation technology, primarily to develop longer-acting proprietary versions of already approved therapeutic proteins that currently generate billions of dollars in annual global sales.  The CTP technology is applicable to virtually all proteins.  PROLOR is developing a long-acting version of human growth hormone, which successfully completed a Phase II clinical trial.  It also is developing long-acting versions of Factor VIIa and Factor IX for hemophilia and a GLP-1/Glucagon dual receptor agonist peptide for diabetes and obesity, all of which are in preclinical development.  For more information, visit www.prolor-biotech.com.

Safe Harbor Statement:  This press release contains forward-looking statements, which may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "would", "intends," "estimates," "suggests," "has the potential to" and other words of similar meaning, including statements regarding the results of current clinical studies and preclinical experiments and the effectiveness of PROLOR's long-acting protein programs, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. 
'/>"/>

SOURCE PROLOR Biotech, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. GenWay Biotech Appoints New Vice President of Custom/OEM
2. Amarantus BioSciences to Present at the New York Biotechnology Association (NYBA) 21st Annual Meeting on May 2nd, 2012
3. Johnson & Johnson (China) Investment Ltd. Acquires Guangzhou Bioseal Biotechnology Co., Ltd.
4. Stiefel, a GSK company, enters agreement with Welichem Biotech, Inc. to acquire a novel topical agent for psoriasis and atopic dermatitis
5. TaiGen Biotechnology Out-Licensed China Rights of Novel Antibiotic, Nemonoxacin, to Zhejiang Medicine
6. Lifeline Biotechnologies, Inc. Receives Patent Award, a Device for Breast Tissue Temperature Analysis for Determining Cancer Conditions
7. Obamacare Ruling, Other Pivotal News Rocks Biotech Sector in June
8. Tougher Times May be Ahead for Biotechs: 1H12 Fundraising Slows
9. Last Chance to Save on Boston-Area Mobile Health, Biotech, and Pharmaceutical Conference Registration
10. Early Birds Save Up to $600 on Asian Biotech and Pharmaceutical Conferences
11. Lifeline Biotechnologies First Warning Systems
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... Kalifornien, 28. August 2014 ... Start der Patientenrekrutierung für eine IDE-Pivot-Studie ... zur Beurteilung der Sicherheit und Wirksamkeit ... Aneurysmen („WEB") bekanntgegeben. Adam Arthur, MD, Dozent ... of Neurosurgery/Semmes-Murphey Clinic, und Hauptprüfarzt der ...
(Date:8/28/2014)... ALISO VIEJO, Calif. , Aug. 28, 2014 ... has initiated patient enrollment in an Investigational Device ... and effectiveness of the WEB™ Aneurysm Embolization System ... University of Tennessee Department of Neurosurgery/Semmes-Murphey Clinic and ... first four patients in the study, treating them with ...
(Date:8/28/2014)... 28, 2014 GenSpera, Inc. (OTCQB: GNSZ), a ... cancer, announces the recent publication of the article "Targeting ... The recent article co-authored by Doan, et ... of GenSpera,s prodrug technology platform that is designed to ... plant Thapsia garganica ) directly to tumors. These ...
Breaking Medicine Technology:Sequent Medical kündigt Start einer IDE-Studie für das WEB System zur Embolisation von Aneurysmen bekannt 2Sequent Medical kündigt Start einer IDE-Studie für das WEB System zur Embolisation von Aneurysmen bekannt 3Sequent Medical Announces Initiation Of IDE Study For The WEB Aneurysm Embolization System 2Sequent Medical Announces Initiation Of IDE Study For The WEB Aneurysm Embolization System 3GenSpera Media Advisory; "Targeting thapsigargin towards tumors" Published in Steroids 2GenSpera Media Advisory; "Targeting thapsigargin towards tumors" Published in Steroids 3
... GNVC ) announced that Adel A.F. Mahmoud, M.D., ... the Company,s Board of Directors at its annual meeting of ... "Drs. Mahmoud and Connor bring a wealth of experience, especially ... expand the breadth and scope of our vaccine programs there ...
... June 22, 2011 Genesis Biopharma, Inc. (OTC/BB: GNBP), ... that it will hold a conference call with the ... Eastern (9:00 a.m. Pacific).  The Company,s Chairman and Chief ... on the business, and discuss the clinical and commercial ...
Cached Medicine Technology:GenVec Elects Adel A.F. Mahmoud and Edward M. Connor, Jr. to Board of Directors 2GenVec Elects Adel A.F. Mahmoud and Edward M. Connor, Jr. to Board of Directors 3GenVec Elects Adel A.F. Mahmoud and Edward M. Connor, Jr. to Board of Directors 4Genesis Biopharma to Hold Business Update Conference Call on June 29 2
(Date:8/28/2014)... TX (PRWEB) August 28, 2014 After ... Dr. Paul Vitenas is excited to announce the ... of its kind in any city, Mirror Mirror Beauty ... building. , Situated on the corner of Richmond and ... modern architecture, luxurious amenities, and cutting-edge technology in a ...
(Date:8/28/2014)... Having greater amounts of yellow pigment in your eyes ... hazy conditions, a new study reports. In a ... in order to test the distance vision of people ... pigment) in their eyes. The volunteers had widely ... the nutrients lutein and zeaxanthin, according to the researchers, ...
(Date:8/28/2014)... The Foundation for Women’s Cancer ... September by alerting women to the link between obesity ... symptoms of endometrial cancer. , Endometrial cancer is ... common cancer. More than 52,600 will learn of a ... women with weight management challenges to know the early ...
(Date:8/28/2014)... Diego, CA (PRWEB) August 28, 2014 Vitals, ... has named Dr. Sabrina Fabi of Cosmetic Laser Dermatology one ... allows hundreds of thousands of patients to share their doctor ... including bedside manner, face time, and follow-ups. The Vitals Top ... in California, Dr. Fabi was ranked one of the highest ...
(Date:8/28/2014)... 28, 2014 Dr. Bryan McIntosh of ... ebook guide to the tummy tuck cosmetic procedure, ... the procedure itself, and how to recover well afterwards. ... explanations. Dr. McIntosh also discusses how to have accurate ... that the procedure is as successful as possible. , ...
Breaking Medicine News(10 mins):Health News:Mirror Mirror Beauty Boutique to Welcome Its First Patients 2Health News:Eye Pigment May Help Vision in Hazy Conditions 2Health News:Foundation for Women's Cancer Alerts Women to Link Between Obesity and Endometrial Cancer 2Health News:Dr. Sabrina Fabi of Cosmetic Laser Dermatology Recognized as Vitals Top 10 Doctor 2Health News:The Ultimate Guide to the Tummy Tuck Surgery eBook is Released by Dr. Bryan McIntosh 2
... networks begin with one altruistic living donor, study explains, ... one healthy young man stepped forward, willing to give ... years later, 10 people had received new kidneys from ... donation started the first nonsimultaneous, extended altruistic-donor (NEAD) chain. ...
... report finds , , WEDNESDAY, March 11 (HealthDay News) -- Thousands ... by atmospheric ozone, a new study finds. , The greatest ... such as Los Angeles, which has one of the highest ... 25 percent to 30 percent higher annual risk of dying ...
... The Coalition for Ethical Imaging (CEI), a grassroots ... in Texas, has announced its support for Senate Bill ... bill in the House, House Bill 2599 by Rep. ... patient care and safety in the state of Texas ...
... BALTIMORE, March 11 The Open Society Institute,s Closing ... exist for the new Director of the Office of ... the United States, approach to the problem of addiction. ... Gil Kerlikowske,s official nomination as the nation,s "drug czar," ...
... Kidney Month Briefing Reveals Majority of New Kidney Failure ... Disproportionate Rates -WASHINGTON, March 11 Kidney Care Partners ... dialysis professionals, care providers and manufacturers working together to ... disease and kidney failure -- in partnership with the ...
... The American Association of Oral and Maxillofacial Surgeons ... on her recent introduction of H.R. 1339, the ... , which would require insurance plans, including those which ... (ERISA) , that provide surgical benefits, to cover reconstructive ...
Cached Medicine News:Health News:Living Kidney Donation Chains May Help More Get Transplants 2Health News:Living Kidney Donation Chains May Help More Get Transplants 3Health News:Ozone Pollution Taking Toll on American Lives 2Health News:Ozone Pollution Taking Toll on American Lives 3Health News:The Coalition for Ethical Imaging Announces Support for Diagnostic Imaging Bills Introduced in Texas Legislature 2Health News:The Coalition for Ethical Imaging Announces Support for Diagnostic Imaging Bills Introduced in Texas Legislature 3Health News:Closing the Addiction Treatment Gap Initiative Highlights Opportunities for New 'Drug Czar' 2Health News:Kidney Care Partners and National Minority Quality Forum Call for Prevention Programs in Disease 'Hot Spots' 2Health News:Kidney Care Partners and National Minority Quality Forum Call for Prevention Programs in Disease 'Hot Spots' 3Health News:Oral and Maxillofacial Surgeons Applaud Congresswoman McCarthy's Legislation to Require Insurance Coverage for Children With Congenital Deformities 2Health News:Oral and Maxillofacial Surgeons Applaud Congresswoman McCarthy's Legislation to Require Insurance Coverage for Children With Congenital Deformities 3
The Osteomark NTx Point of Care (POC)device allows physicians to monitor their patients response to anti-resorptive drugs as early as 3-6 months from starting treatment. Osteomark NTx shows you and y...
... 50 analyzer is an ... offices and smaller laboratories ... of state-of-the-art instrument-based testing ... efficient way to obtain ...
... Hemoglobin Test Systems provide ... quantitative hemoglobin results with ... a large hematology analyzer. ... of either the B-Hemoglobin ...
... a qualitative immunoassay for urinary albumin that ... This albumin specific, CLIA Waived test has ... of 95%, and gives accurate results in ... up to 8 hours. Since early detection ...
Medicine Products: